Estimating drug efficacy and viral dynamic parameters: HIV and HCV

  title={Estimating drug efficacy and viral dynamic parameters: HIV and HCV},
  author={Alan S. Perelson and Ruy M. Ribeiro},
  journal={Statistics in Medicine},
Mathematical models have proven valuable in understanding the in vivo dynamics of human immunodeficiency virus type 1 (HIV‐1), the virus that causes AIDS, and hepatitis C virus (HCV), the virus that causes hepatitis C infection. By comparing mathematical models with the data obtained from patients being treated with antiviral drugs, it has been possible to determine many quantitative features of these infections. The most dramatic finding has been that even though AIDS and hepatitis C are… 

Spatial Aspects of HIV Infection

Most mathematical models applied to experimental data on viral infections have been formulated as systems of ordinary differential equations (ODE) which have helped to improve understanding of the infection as well as the dynamics of the immune response.

The Roles of Stochasticity and Life History in the Evolutionary Population Dynamics of Pathogens

This work presents a unified model of viral population dynamics within a host, which can capture a variety of viral life cycles and finds that the mutation-selection balance attained prior to treatment depends on the step at which mutations occur and the viral trait that incurs the cost of resistance.

Mathematical modeling of within‐host Zika virus dynamics

A mathematical modeling approach for analyzing the within‐host dynamics of Zika virus is outlined, and how these models can be used to understand key aspects of the viral life cycle and to predict antiviral efficacy is described.

Modelling Degradation and Replication Kinetics of the Zika Virus In Vitro Infection

A model, in which inactivation of infectious ZIKV is gamma distributed and fit the model to the temporal measurements of infectious virus remaining in the media is proposed and provides a well-described example of non-exponential viral decay dynamics and presents numerical characterization of in vitro infection with ZikV.

HIV evolution and progression of the infection to AIDS.

Impact of Latently Infected Cells on Strain Archiving Within HIV Hosts

It is found that although short term archiving of viral strains is possible in a model with no mechanism for reservoir maintenance, both bystander proliferation and asymmetric division of latent cells allow archiving to occur over much longer timescales.

Modeling the Mechanisms by Which HIV-Associated Immunosuppression Influences HPV Persistence at the Oral Mucosa

A mathematical model of HIV/HPV co-infection is developed and predicts that, under efficacious antiretroviral treatment, HPV infections will decrease in the long run due to the restoration of CD4+ T cell numbers and protective immune responses.

Practical evaluation of a mouse with chimeric human liver model for hepatitis C virus infection using an NS3-4A protease inhibitor.

A mathematical model analysis of viral kinetics suggested that 1 g of the chimeric human liver could produce at least 10 virions per day, and this may be comparable to HCV production in the human liver.

Mathematical Models of Immune Responses to Infectious Diseases

A mathematical model of HIV/HPV co-infection and the role of HIV-associated immune suppression in HPV persistence and pathogenesis is developed, and it is concluded that 3BNC117 elicits both neutralizing and non-neutralizing effects across most patients.



Mathematical Analysis of HIV-1 Dynamics in Vivo

It is shown how dynamical modeling and parameter estimation techniques have uncovered important features of HIV pathogenesis and impacted the way in which AIDS patients are treated with potent antiretroviral drugs.

Modeling viral and drug kinetics: hepatitis C virus treatment with pegylated interferon alfa-2b.

Models incorporating pharmacokinetic/pharmacodynamic analysis into a model of viral dynamics are needed to correctly interpret viral load changes and estimate drug effectiveness in treatment protocols using peginterferon alfa-2b.

Hepatitis C Viral Dynamics in Vivo and the Antiviral Efficacy of Interferon-α Therapy

Findings show that infection with hepatitis C virus is highly dynamic and that early monitoring of viral load can help guide therapy, with blocking efficacies of 81, 95, and 96% for daily doses of 5, 10, and 15 million international units, respectively.

Differences in viral dynamics between genotypes 1 and 2 of hepatitis C virus.

The better response rate of patients infected with HCV genotype 2 is multifactorial, the first finding of a difference in viral dynamics between subtypes of the same virus and demonstrates the importance of subtype-specific virus-host-drug interactions.

Modeling Long-Term HIV Dynamics and Antiretroviral Response: Effects of Drug Potency, Pharmacokinetics, Adherence, and Drug Resistance

A drug efficacy threshold for each patient is estimated that can be used to assess whether an ARV regimen is potent enough to suppress HIV viruses in the individual patient and the proposed mathematic models and statistical techniques may provide a framework to simulate and predict antiviral response for individual patients.

Modeling plasma virus concentration during primary HIV infection.

It is illustrated that two possible immune response mechanisms, cytotoxic T lymphocyte destruction of infected target cells and cytokine suppression of viral replication, could account for declines in viral load data not predicted by the original target-cell-limited model.

Effect of ribavirin on hepatitis C viral kinetics in patients treated with pegylated interferon

The third‐phase decay of initial viral kinetics was more pronounced in patients treated with peginterferon α‐2a plus ribavirin, suggesting that combination treatment leads to a better restoration of the patient's immune response.

Viral dynamics and response differences in HCV‐infected African American and white patients treated with IFN and ribavirin

The failure of IFN response in African American patients infected with genotype 1 HCV is in part due to an impaired ability to inhibit viral production.